Business Wire

PA-BOOMI

8.5.2024 18:01:35 CEST | Business Wire | Press release

Share
Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024

Boomi™, the intelligent integration and automation leader, today unveiled its vision for the company’s future, along with strategic acquisitions and key product announcements at Boomi World 2024. With more than 20,000 global customers and a network of approximately 800 partners worldwide, Boomi is leading the industry towards the future with a focus on integration and automation, API management, and data management, all made more important and powerful than ever with the emergence of the AI economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508488304/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024 (Graphic: Business Wire)

In his keynote, Boomi CEO Steve Lucas emphasized the transformative impact of integration platform as a service (iPaaS), spotlighting its pivotal role in enhancing speed, agility, and effectiveness across business operations. Lucas explained how Boomi’s iPaaS streamlines connectivity — seamlessly linking people, systems, devices, and applications — for building stronger relationships and enabling swift, informed decision-making through real-time data access.

But Boomi recognizes the opportunity to take connectivity even further, and to bring connectivity solutions to more companies in more areas of business and IT.

“Connectivity,” Lucas pointed out, “remains a critical challenge for almost every organization. The chief culprit is digital fragmentation, a byproduct of digital shifts that, paradoxically, lead to digital silos and disjointed technical architectures that leave the average enterprise now juggling over 364 applications and numerous API gateways.”

The emergence of the AI economy has further highlighted the challenges of digital fragmentation. "AI thrives on reliable, secure, and current data, yet too often, this data is fragmented, difficult to govern, and not securely managed," Lucas noted. “What companies urgently need is a unified, enterprise-scale platform that not only bridges APIs, applications, data, and AI models, but also accelerates digital transformation.”

To address these pressing challenges, Boomi unveiled key announcements at Boomi World, including:

New Boomi Enterprise Platform Vision

Boomi has expanded and deepened the capabilities of the Boomi Enterprise Platform with:

  • Next-generation API management for the AI economy
  • An AI agent framework that provides out-of-the-box AI agents, pluggability for 3rd party AI agents, as well as the ability to automate AI orchestration workflows
  • Enhanced data management to support data quality, data lineage, and metadata management

Next-Generation API Management for the AI Economy

Joining Lucas onstage, Matt McLarty, CTO at Boomi, explained that “companies today suffer from API sprawl: API gateways are everywhere, and there’s no effective global view or management dashboard for discovering, governing, and securing them, let alone rationalizing API investments and promoting best-in-class APIs for adoption. The AI economy requires next-generation API management (APIM) that accounts for a fragmented APIM landscape and can handle the demands of enterprise-grade scalability and security that AI workloads place on APIM solutions.”

To solve this problem, Boomi announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group. Both acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end enterprise platform.

Boomi AI Agent Framework

To accelerate innovation in the AI economy, Boomi introduced the Boomi AI agent framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.

Boomi introduced four new agents built into the platform that make use of the new AI agent framework, including:

  • Boomi Answers: Agent for providing prescriptive help
  • Boomi DataDetective: Agent for classifying data fields, protecting sensitive data like personally identifiable information (PII), and tracking where data is being moved
  • Boomi DesignGen: Agent for autonomously building integrations
  • Boomi Scribe: Agent for automatically documenting existing and built-by-AI integrations

In addition, the Boomi AI agent framework is open to third parties, and supports pluggable AI agents, allowing customers to integrate third-party AI agents into the platform via APIs or Boomi GPT.

In his Boomi World keynote, Lucas announced a strategic OEM agreement with Vianai Systems, a leading provider of conversational AI solutions for finance, and demonstrated one of the first third-party AI agents, Boomi FinTalk powered by Vianai. Customers can seamlessly connect to Boomi FinTalk powered by Vianai via Boomi GPT, leveraging Boomi’s AI agent framework. Using Boomi, the agent connects to sources of financial data in ERP systems, databases, documents, customers’ data lakes, and other data, and enables users to ask questions of their data through a natural language interface to discover and analyze financial data and trends in real-time, for immediate actionable insights.

“Technology and business leaders have struggled to leverage the power of generative AI in their enterprises due to the very real issues of accuracy and security, relevance to business users with domain-specific requirements, and the inability to query both structured and unstructured data and systems in natural language,” said Dr. Vishal Sikka, Founder and CEO, Vianai Systems. “With Boomi FinTalk powered by Vianai, we are solving these issues with Boomi’s vast integration capabilities and Vianai’s conversational AI application for CFOs and finance users, enabling real-time, accurate, and actionable insights to drive business transformation.”

Trusted Data Management

Boomi also announced Boomi DataHub, a trusted data foundation for operational, analytical, and AI workloads. A high velocity, high quality data access layer, Boomi DataHub provides master data management, integration pipelines, and a framework that will expand over time to provide other data management capabilities, including enterprise scale movement and standardization of data for AI and analytics initiatives.

“Centralizing data has proved to be a dead end for companies,” said Lucas. “A better approach is to build connectivity, governance, and automation into the IT resources companies already have, taking advantage of AI to make this work faster and easier than ever before. With the Boomi Enterprise Platform, we’re giving customers the foundation they need for connecting and managing all their data, and for accelerating AI and API development. Using Boomi, customers can say goodbye to the digital fragmentation that’s been undermining their digital transformation efforts, and finally get the comprehensive visibility, control, and automation they need.”

Check out all the latest announcements from Boomi World 2024 here.

Additional Resources

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508488304/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye